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Abstract
Background: Breast cancer is a leading cause of cancer-related death in women worldwide. Despite extensive studies
in all areas of basic, clinical and applied research, accurate prognosis remains elusive, thus leading to overtreatment of
many patients. Diagnosis could be improved by introducing multigene molecular scores in standard clinical practice.
Several tests that work with formalin-fixed tissue have become routine. Molecular scores usually include several genes
representing processes, response to oestrogens, progestogens and human epidermal growth factor receptor 2 (Her2),
respectively, which are combined additively in single values. These multi-gene scores have the advantage of being
more robust and reproducible than single-gene scores. Their utility may be further enhanced by combining them with
classical diagnostic parameters. Here, we present an exploratory study comparing the RISK and research versions of
Oncotype DX recurrence score (RS), Prosigna Risk of Recurrence (ROR) and EndoPredict (EP) with respect to their
prognostic potential for ipsilateral recurrence and/or distant relapse in brain, and we compared the scores to the
intrinsic subtypes based on PAM50.
Methods: RNA was extracted from formalin-fixed, paraffin-embedded (FFPE) tissue cores of primary tumours, local
recurrences and brain metastases. Gene expression was measured on a NanoString nCounter Analysis System. Intrinsic
subtypes and molecular scores were computed according to published literature and RISK, RS, ROR and EP were
compared against each other and to the intrinsic subtypes Luminal A (lumA), Luminal B (lumB), Her2-enriched (Her2↑),
Basal-like (basal), and Normal-like (normal) of PAM50. Local recurrences and brain metastases were compared to their
corresponding primary tumours.
Results: All four molecular scores were highly correlated. Highest correlations were observed among genes related to
proliferation while lower correlations were found among oestrogen-related genes. The scores were significantly higher
in primary tumours progressing to brain metastases as compared to recurrence-free primary tumours and primary
tumours that relapsed as local recurrences.
Conclusions: RISK and ROR-P are prognostic for primary tumours metastasizing to the brain. All four scores, RISK, RS, EP
and ROR-P failed to discriminate between primary tumours that remained recurrence-free and primary tumours
relapsing as local recurrences.
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In spite of early detection, accurate classification and opti-
mal treatment, about 30% of patients with early breast
cancer will suffer a locoregional or a distant recurrence
[1]. Recurrent breast cancer can develop in essentially any
organ of the body; metastases are more aggressive than
the primary tumour and account for the majority of
deaths related to breast cancer. Many locoregional recur-
rences can be controlled initially, but they are associated
with a high risk of distant metastasis and death [2, 3].
Traditionally, several parameters are related to the risk of
recurrence and to the response to drug therapy, e.g.
tumour size, histological grade and proliferation, lymph
node involvement, lymphovascular invasion, overexpres-
sion and/or amplification of the human epidermal growth
factor receptor 2 (Her2) gene and failure to express the
oestrogen receptor (ER) and progesterone receptor (PR).
More recently, several robust molecular scores have been
developed. Each score is based on a rather simple algo-
rithm integrating expression levels of several genes. Such
scores are correlated with prognosis and their values are
more stable than expression values of individual genes.
Starting with the seminal work of Perou et al. [4] and
Sørlie et al. [5], through iterative refinements, a set of
stable molecular subgroups (intrinsic subtypes) of breast
cancer was identified from microarray data with thou-
sands of genes. Fifty genes were sufficient to reliably
classify breast cancer into the five intrinsic subtypes:
Luminal A (lumA), Luminal B (lumB), Her2-enriched
(Her2↑), Basal-like (basal) and Normal-like (normal) [6,
7]. The intrinsic subtypes are important parameters as
they added independent prognostics (survival of pa-
tients) [4, 5] to the classical risk factors and predictors
[6, 7]. The PAM50 was further developed to a commer-
cial test made by NanoString under the brand Prosigna.
It identifies the intrinsic subtype and provides the risk of
(distant) recurrence (ROR-P) [8]. The Oncotype DX® re-
currence score (RS) provides information about the risk
of distant recurrence [9, 10] as well as the benefit of
chemotherapy in ER+/Her2- breast cancer patients [11].
The RS assay has been clinically validated and the test is
performed at the central clinical reference laboratory of
Genomic Heath, Inc. EndoPredict (EP) and EPclin,
which is a combination of EP with tumour size and
nodal status, predict distant recurrence and they can be
applied to ER+/Her2- breast cancers [12]. EP also pre-
dicts response to chemotherapy in ER+/Her2- breast
cancer patients [13] and is available as a commercial test
as well. The RISK score predicts disease free survival in
patients with ER+ breast cancer [14]. Even though these
scores combine genes related to proliferation and ER,
the overlap between them is reduced or non-existent.
The RISK and RS also contain two genes overexpressed
in Her2↑ tumours: ERBB2 (the gene coding for Her2)
and GRB7 (the gene is linked to ERBB2 on chromosome
17). While multigene molecular risk scores have im-
proved the prediction of distant recurrence, their ability
to predict ipsilateral local recurrence has remained
uncertain.
In this study, we compared four multigene risk scores
(research versions of RISK, RS, ROR-P and EP) and con-
trasted them with the intrinsic subtypes built from
PAM50. The scores of recurrence-free patients and pa-
tients who later developed an ipsilateral local recurrence
or a brain metastasis were compared, as well as the ex-
pression pattern between primary tumours and their
matched local recurrences or brain metastases. Our re-
sults revealed that RISK, RS, ROR-P and EP show an
amazingly similar performance with respect to their risk
of recurrence. All four scores failed completely to dis-
criminate between primary breast cancer that remained
recurrence-free (curated control patients) and primary




Archival material was collected retrospectively from
formalin-fixed paraffin-embedded (FFPE) tumour sam-
ples from the repository of the Swiss Sentinel Node
Study and the Biobank Bern. Eighty-seven samples were
from primary tumours, 43 from patients without local or
distant recurrence (controls); 25 from patients who de-
veloped local recurrence in the residual breast paren-
chyma in the same quadrant and 19 from patients who
developed brain metastasis. In addition, tumour tissues
derived from 20 local recurrences and 25 brain metasta-
ses were obtained from the Biobank Bern. Primary tu-
mours and local recurrences were available for 19
patients, while primary tumours and brain metastases
were available also for 19 patients. Median follow-up
time of recurrence-free patients was 88 months. The
study was approved by the Cantonal Ethics Committee
of the Canton Bern (Ref 2017–02025). Primary tumours
were diagnosed between 1987 and 2009. Tumours were
removed by breast conservative surgery and treated
postoperatively with radiotherapy. Patients with uncer-
tain or positive resection margins were excluded from
the study. Patients were treated with chemotherapy and
adjuvant treatment depending on hormone receptor sta-
tus and tumour stage.
Immunohistochemistry (IHC)
The ER and the PR were measured immunohistochemi-
cally using 1% labelling as threshold for negative (−) and
positive (+) staining. The Her2 was measured immuno-
histochemically. Staining was defined as negative
(Her2 = 0 or 1+) or positive (Her2 = 3+); tumours with
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partial membrane staining of more than 10% tumour
cells (Her2 = 2+) were reanalysed by Fluorescence In
Situ Hybridization (FISH), according to the ASCO-CAP
guidelines [15]. Proliferation was measured with a
monoclonal antibody against Ki-67 (MIB-1) and
expressed as labelling index (LI). As thresholds for low
and high Ki-67, LI < 14% and LI ≥ 14% were used,
according to Cheang and coworkers [16].
The IHC-based classification was used to build immu-
nohistochemical surrogates of intrinsic subtypes as de-
scribed by Guiu et al. [17]. Each tumour was assigned to
one of the four classes: lumA (ER+ and/or PR+, Her2–
and Ki-67 LI low), lumB (ER+ and/or PR+, Her2– and
Ki-67 LI high, or ER+ and/or PR+, Her2+ and Ki-67 LI
low or high), Her2↑ (ER–, PR– and Her2+) and basal
(ER–, PR– and Her2–). Normal-like tumours were not
considered for this classification. The PAM50-based in-
trinsic subtype prediction was performed as described
[18]. The RISK and the risk of recurrence, ROR-P, were
determined from all the 132 tumours, the Oncotype DX
recurrence score, RS, and EndoPredict, EP, were deter-
mined from ER+ and Her2– tumours (based on IHC).
RNA isolation and processing
Two core punches of FFPE material were prepared based
on a local inspection of tumour blocks, the paraffin was
dissolved, and the RNA subjected to demodification and
purification on silica-based columns (AmpTec GmbH,
Hamburg, Germany), as described previously [19, 20].
Seven samples were discarded due to poor quality of
RNA or insufficient recovery. The remaining 132 RNAs
were used for gene expression analysis.
Eighty-four test and twelve reference genes were mea-
sured on a NanoString nCounter System (NanoString
Technologies, Seattle USA). The genes are listed in add-
itional file 1. Eight negative controls (no homology to
eukaryotic RNA) and six positive probes (directed
against unrelated RNA) were also included. The RNAs
corresponding to the positive probes (spike-in RNAs)
are present in each sample before hybridization. One
hundred ng RNA was hybridized overnight at 65 °C and
processed on an nCounter Prep Station. Gene expression
was then quantified with a Digital Analyzer. The proced-
ure is completely enzyme-free and highly robust regard-
ing RNA fragmentation. The raw signal for each gene
was background corrected and normalized using the
negative and positive control genes in each sample. The
resulting data was highly reproducible and NanoString
data correlated with microarray data or real-time PCR
data [21]. The expression data was further normalized
against internal reference genes and log2 transformed to
determine the intrinsic subtypes and the molecular
scores of each sample (see below). Raw data is shown in
additional file 3.
Normalization of gene expression data
The raw expression data from the Digital Analyzer was
normalized using nSolver version 3.0 (NanoString Tech-
nologies, Seattle USA) or NanoStringNorm R package
[22]. Both analyses gave the same results (data not
shown). Briefly, the expression data was background cor-
rected and poor-quality samples were excluded. The data
of all the remaining 132 samples were normalized using
all the 12 reference genes (reference genes are listed in
additional file 1). The normalized data were then sub-
jected to a hierarchical cluster analysis [23] based on the
union of 74 genes of PAM50, RISK, RS and EP in nSol-
ver (version 3.0) using Euclidean distance.
The PAM50 and the molecular scores were originally
developed from microarray data or from real-time PCR
data. Erroneously, the probes for CDC6 and CDCA1
which are part of PAM50 classifier were missing in the
CodeSet during hybridization. To assess the effect of the
two genes on the stability of PAM50 predictions, we com-
pared the subtype assignments made by PAM50 classifier
(R package genefu with robust standardization [18]) on
two publicly available data sets [24] [25] with and without
the two genes. Globally, < 3% of samples (7 from [24] and
3 from [25], respectively) changed their subtype when
CDC6 and CDCA1 were discarded. Thus, we considered
that the assignment without the two genes was stable
enough to assign all 87 primary and 45 recurrent cancers
to one of the five classes: normal, lumA, lumB, Her2↑ and
basal [18].
Analysis of molecular scores
The NanoString data was normalized separately for each
molecular score using the procedures and reference
genes described for each score: three reference genes for
RISK [14], five reference genes for RS [10] and three ref-
erence genes for EP [12]. The genes for ROR-P are part
of PAM50; therefore, normalized PAM50 data was used.
Threshold cutoffs and re-scaling of RS (0–100) were
omitted as the scores were exclusively used for relative
comparison with other scores or with PAM50 subtypes.
The RISK, RS and EP were computed from at least two
groups of functionally related genes, where the first
group comprised genes reflecting the proliferative poten-
tial of tumour cells (termed PRO-subscore), and the sec-
ond group integrated the capacity of tumour cells to
respond to steroid hormones and their receptors
(oestrogen and progesterone and their receptors). They
were termed ER- and PR-subscore. A PRO-subscore was
also computed from the ROR-P score [6], based on the
proliferation-related genes in PAM50.
Statistical analysis
The intrinsic subtypes were determined based on immu-
nohistochemical data [17] and on gene expression [18].
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The agreement between the IHC and PAM50 classifica-
tions was measured in terms of Cohen’s kappa statistic.
Only the tumours with lumA, lumB, Her2↑ or basal
classification were included for this comparison, since
normal-like tumours were not mapped to an IHC-
defined subtype.
The agreement between scores was estimated with
Cohen’s kappa statistics categorizing one-third of sam-
ples into high risk and two-thirds of samples into
intermediate-low risk. The significance level was set a
priori to p = 0.05 for all tests. The correlations between
molecular scores and subscores were evaluated using
Spearman’s correlation test.
Each molecular score was compared within PAM50
intrinsic subtypes (lumA, lumB, Her2↑, basal and nor-
mal) using the Mann-Whitney test. Similarly, molecular
scores and subscores were compared between groups of
samples (primary tumours from controls, primary tu-
mours from patients who developed local recurrence,
primary tumours from patients who developed brain
metastasis, local recurrences and brain metastases).
Results
Comparison of gene expression and
immunohistochemistry
This study is based on 87 primary breast cancers, 20
local recurrences and 25 brain metastases. Forty-three
primary tumours remained recurrence free, 19 patients
had a local recurrence and 25 had a brain metastasis.
Clinical characteristics of patients and histological data
of primary and recurrent tumours are summarized in
Table 1 together with immunohistochemical data on the
ER, the PR, Her2 and Ki-67 (Table 1).
In a first comparison, the RNA-based expression of ER
(ESR1), PR (PGR) and Her2 (ERBB2) was compared to
the immunohistochemical data for the respective pro-
teins (additional file 2, panels A-C). Similarly, the ex-
pression of Ki-67 (measured with the probe MKI67) was
compared to the proliferation marker Ki-67. The Ki-67
was quantified as labelling index (LI) with a monoclonal
antibody against Ki-67 (MIB-1) (additional file 2, panel
D). The Ki-67 was dichotomized into low (LI < 14%
immunostaining with MIB-1) and high (LI ≥ 14% immu-
nostaining with MIB-1) as described previously [16].
The comparison of immunohistochemistry data and
gene expression data revealed excellent concordance be-
tween all four markers.
Intrinsic subtypes were also built from IHC data of the
tumours [17] (Table 1). The procedure is described in
the Methods section. The subtypes according to IHC
were compared to subtypes according to gene expression
(PAM50). The agreement between the two classifications
was only moderate (Cohen’s kappa, κ = 0.58). The dis-
cordances between classifications were 33, 49, 17 and
18% for lumA, lumB, Her2↑ and basal subtypes, respect-
ively. Tumours with normal-like classification were
omitted from this comparison.
Hierarchical clustering of primary breast cancer, local
recurrences and distant metastases
Primary tumours, local recurrences and distant metastases
were then characterized on the basis of gene expression.
Gene expression was measured with NanoString and the
raw data was normalized using 12 reference genes, repre-
senting a combination of five reference genes for PAM50,
three for RISK, five for RS and three for EP. The test and
reference genes are listed in additional file 1. The 132 tu-
mours were characterized by hierarchical clustering using
all the 74 genes represented in PAM50, RISK, RS and/or
EP. The result is shown as a heatmap (Fig. 1, panel a), with
genes by columns and tumours by rows. Tumours that
remained recurrence-free were termed controls, and are
marked with white boxes in panel B; primary tumours that
relapsed as local recurrence and local recurrences are
marked with grey boxes (panel B); and primary tumours
that progressed to brain metastases and brain metastases
are marked with black boxes (panel B). Recurrence-free
controls and local recurrences (primary tumours and re-
currences) predominantly clustered in the upper part of
the heatmap while primary tumours metastasizing to the
brain and brain metastases are more abundant in the
lower part (panel B). Intrinsic subtypes [7] are symbolized
with colours (panel C) according to Parker et al. [7]: nor-
mal (ochre), lumA (light blue) and lumB (blue), Her2↑
(pink) and basal (brown). Normal and lumA are predom-
inantly in the upper part, Her2↑ and basal in the lower
part of the heatmap. The majority of lumB are between
these two clusters.
Twenty-five tumours were primary tumours that pro-
gressed to local recurrences and 20 were local recurrences.
Corresponding tissue from primary and recurrence tu-
mours was available from 19 patients marked as P1 – P19
for primaries and R1 – R19 for recurrences (panel D). The
analysis of these pairs of tumours showed that, to the ex-
tent of genes considered here, they were not particularly
similar, with only three pairs clustering together.
Similarly, among the 44 primary tumours and brain
metastases 19 were matched samples, primary tumours
are labelled P20 – P38 and metastases were labelled
M20 – M38 (panel E). It may be worth mentioning that
11 pairs of primary metastases from the same patients
clustered in the immediate vicinity of each other on the
heatmap (panel E). This clustering may suggest that, at
least with regard to the expression of the genes consid-
ered here, primary tumours and corresponding brain
metastases are more similar to each other than primary
tumours and local recurrences. It is also apparent that
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Table 1 Patient and tumour characteristics
Group Control Local recurrence Brain metastasis
primary local recurrence primary distant metastasis
Nr. of patients (pairs) 43 26 (19 pairs) 25 (19 pairs)
Total number of tumours 43 25 20 19 25
Median age (range) 55 (30–90) 60 (28–85) 56 (35–74)
Menopausal category
Pre-menopausal 15 7 9
Post-menopausal 27 18 10
Unknown/missing 1 0 0
Tumour grade
Grade 1 4 1 1 0
Grade 2 29 18 10 8
Grade 3 10 6 3 11
Unknown/missing 0 0 6 0
IHC parameters
ER status
Positive 37 (86%) 20 (80%) 17 (85%) 6 (32%) 7 (28%)
Negative 6 (14%) 5(20%) 3 (15%) 13 (68%) 18 72%)
PR status
Positive 34 (79%) 16 (64%) 12 (60%) 5 (26%) 5 (20%)
Negative 9 (21%) 9 (36%) 8 (40%) 14 (74%) 20 (80%)
Her2 status
Positive 4 (9%) 4 (16%) 2 (10%) 11 (58%) 14 (56%)
Negative 37 (86%) 20 (80%) 17(85%) 7 (37%) 11 (44%)
Unknown/missing 2 (5%) 1 (4%) 1 (5%) 1 (5%) 0
MIB-1
< 14% 19 (44%) 10 (40%) 6 (30%) 4 (21%) 0
≥ 14% 24 (56%) 14 (56%) 13 (65%) 14 (74%) 25 (100%)
Unknown/missing 0 1 (4%) 1 (5%) 1 (5%) 0
IHC subtype
lumA 18 (42%) 9 (36%) 6 (30%) 0 0
lumB 17 (40%) 10 (40%) 10 (50%) 6 (32%) 7 (28%)
Her2↑ 1 (2%) 3 (12%) 1 (5%) 8 (42%) 11 (44%)
basal 5 (12%) 2 (8%) 2 (10%) 4 (21%) 7 (28%)
Unknown/missing 2 (5%) 1 (4%) 1 (5%) 1 (5%) 0
PAM50 subtype
normal 2 (5%) 3 (12%) 0 1 (5%) 0
lumA 17 (40%) 9 (36%) 6 (30%) 3 (16%) 0
lumB 14 (33%) 8 (32%) 9 (45%) 2 (11%) 4 (16%)
Her2↑ 3 (7%) 4 (16%) 3 (15%) 9 (47%) 15 (60%)
basal 7 (16%) 1 (4%) 2 (10%) 4 (21%) 6 (24%)
Main characteristics of patients and tumours in the following groups: Controls (recurrence-free tumours), Local recurrence (primary tumours and local recurrences)
and Brain metastasis (primary tumours and brain metastases). The size of primary and recurrent tumours was not available.
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Fig. 1 (See legend on next page.)
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primary tumours with enriched Her2 tend to metastasize
to the brain.
Comparison of molecular scores
The gene expression data was also used to compute the
four molecular scores RISK, RS, ROR-P and EP accord-
ing to the published instructions, using the test and ref-
erence genes described for each of them [6, 10, 12, 14]
(see Additional file 1 for the complete list of genes). The
distributions of scores are shown separately for control
tumours and primary tumours that later relapsed as
local recurrence or as brain metastasis. Similarly, the
distributions of scores are shown for local recurrences
and brain metastases. The data for RISK and ROR-P are
based on all available tumours (Fig. 2a). The calculation
of RS and EP is limited to ER+ and Her2- tumours
(Fig. 2b). Only three primary tumours later relapsed as
brain metastases and four brain metastases were ER+
and Her2-, therefore, the corresponding data for these
tumours are not shown. For all four molecular scores,
no statistically significant differences were found be-
tween recurrence-free controls and primary tumours
that later relapsed as local recurrences (Mann-Whitney
test) (Table 2). Recurrence-free controls were also com-
pared to primary tumours that later relapsed as brain
metastases. The RISK and ROR-P scores were higher in
tumours that relapsed as compared to recurrence-free
controls (p < 0.01) and primary tumours that relapsed
as local recurrence (p < 0.01 for RISK and p = 0.03 for
ROR-P). The discrimination between control tumours
and primary tumours of brain metastases was also evi-
dent at the level of the three subscores representing the
hormonal status (ER-, PR and Her2-subscores). The
molecular scores were also compared between primary
(See figure on previous page.)
Fig. 1 Hierarchical clustering of primary tumours, local recurrences and distant metastases. a The gene expression profile of all tumours was
characterized by hierarchical clustering and the results are shown as a heatmap. Rows correspond to the 132 tumour samples and columns
correspond to the 74 genes (which are part of RISK, RS, EP and/or PAM50). b The panel indicates for each sample whether it is a control (white),
a primary tumour that later relapsed as local recurrence (grey) or a primary tumour that later progressed to a brain metastasis (black). The same
colours are used for the local recurrences and brain metastases (grey and black, respectively). c Indicates the intrinsic subtype of each tumor:
normal-like (ochre), lumA (light blue), lumB (blue), Her2↑ (pink) or basal (brown). d Indicates 19 pairs of primary tumours (P1 – P19) and local
recurrences (R1 – R19). Pairs clustering in the vicinity of each other are highlighted with brackets. e. Indicates 19 pairs of primary tumours and
brain metastases. Primary tumours and corresponding metastases are labeled P20 – P38 and M20 – M38, respectively. Pairs of tumors clustering
in the vicinity of each other on the heatmap are depicted with brackets
Fig. 2 RISK, ROR-P, RS, and EP scores in primary tumours and recurrences. a Scatter dot plots (median with interquartile range) of RISK and ROR-P
scores are shown for primary tumours (Controls, Local, Met.) and for recurrences (Local and Met.) The total number of tumours was 132. b Scatter
dot plots (median with interquartile range) of RS and EP scores are shown for 72 ER+/Her2- primary tumours (Control and Local) and recurrences (Local)
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tumours and local recurrences and clearly, they did not
change over time (Table 2). Similarly, the RISK score did
not increase between primary tumours and brain metas-
tases, whereas the ROR-P score increased during pro-
gression from primary tumours to brain metastases
(p = 0.01).
The four scores were directly compared against each
other using correlation plots (Fig. 3a). Depending on the
different comparisons the Spearman’s correlations were
0.65–0.84 and the Cohen’s kappa statistics (for dichoto-
mized versions – see Methods) indicated moderate to sub-
stantial agreement (κ within 0.48–0.67). The results
indicate remarkable similarities between any two scores
and at the same time it is obvious that the correlations are
remarkably high, although in fact they are never very high.
The correlation of all the pairs of scores was di-
vided into PRO- and ER-subscores and analysed sep-
arately (see Methods for further details). Increased
expression of genes related to proliferation produced
higher PRO-subscores indicating poorer prognosis of
the patient. Higher ER-subscore correlates with a
favourable response to steroid hormone-based therap-
ies and therefore correlates with better prognosis. The
PRO-and ER-subscores were determined for RISK, RS
and EP (Fig. 3b and c). Spearman correlations for
each of the comparisons were very strong (ρ ≥ 0.82),
while correlations between ER-subscores were consid-
erably lower (ρ = 0.37–0.75).
Relationship between intrinsic subtypes and molecular
scores in primary and recurrent breast cancer
As implied by the IHC-based definition of intrinsic sub-
types, the PAM50 subtypes were aligned with the mo-
lecular scores, in the sense that the scores generally
increased from lumA to lumB, Her2↑ and basal, respect-
ively. In Fig. 4, the classification into normal, lumA,
lumB, Her2↑ and basal subtypes is shown separately for
RISK, ROR-P, RS and EP. Since the RS and EP were
developed for ER+ and Her2– tumours, and the tests
were not validated for ER– and/or Her2+ tumours, the
respective scores are marked distinctly. The scores were
lowest for lumA tumours and significantly higher in
lumB tumours. The scores of lumA and lumB tumours
were significantly lower than the scores of Her2↑ and
basal subtypes (Table 3) which were similar. The mo-
lecular scores of normal tumours tended to be higher
for lumA tumours. The comparison between normal
and lumB led to a less clear picture: the molecular scores
were higher in lumB tumours than in normal-like tu-
mours, with respect to ROR-P, they were not different
with respect to the three other scores (Table 3).
Discussion
Multigene molecular risk scores aim to stratify patients
into risk of recurrence groups. In this study we mea-
sured the expression of genes of the PAM50 signature
and four prognostic scores (RISK, RS, ROR-P and EP) in
Table 2 Comparison of molecular scores between control tumours, local recurrence and brain metastasis
Local recurrence Brain metastasis
primary local recurrence primary distant metastasis
RISK control 0.16 0.03 < 0.01 < 0.01
primary local 0.52 < 0.01 < 0.01
recurrence < 0.01 < 0.01
primary distant 0.34
RS control 0.45 0.01 – –
primary local 0.09 – –
recurrence – –
primary distant –
ROR-P control 0.54 0.16 < 0.01 < 0.01
primary local 0.35 0.03 < 0.01
recurrence 0.35 < 0.01
primary distant 0.01
EP control 0.2 0.05 – –
primary local 0.36 – –
recurrence – –
primary distant –
RISK and ROR-P scores were calculated from all 132 samples, RS and EP scores from 72 ER+/Her2- samples as described. Scores in each group were compared
using the Mann-Whitney test. Shown are p-values of all pairwise comparisons. Two-tailed p values > 0.05 were considered not significant.
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Fig. 3 Comparison of molecular scores. aMolecular scores were determined from primary tumours and pairwise comparisons are shown as scatter plots. Spearman’s
correlation coefficients (ρ) and Cohen’s kappa (κ) are shown in the inset. For κ, low and intermediate scores (2/3 of samples) were compared to high scores (1/3 of
samples). b Genes related to proliferation were used to determine proliferation-related subscores of RISK (RISKPRO), RS (RSPRO), ROR-P (ROR-PPRO) and EP (EPPRO). Pairwise
correlations of subscores are plotted and Spearman’s correlation coefficients (ρ) of subscores are shown in the inset. c Similarly, ER-subscores were calculated from ER-
related genes in RISK (RISKER), RS (RSER) and EP (EPER). Pairwise comparisons of subscores and Spearman’s correlation coefficients (ρ) are shown
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primary breast cancer, in local recurrences and in brain
metastases. We compared primary tumours from
patients that remained recurrence-free (controls) with
primary tumours that relapsed as local recurrences or
primary tumours that relapsed as brain metastases, and
we compared primary tumours with matched local re-
currences or brain metastases.
We are aware of the limitations of our study, since the
patients in our cohort were selected retrospectively and
based on availability of tumour material. Thus, the hy-
potheses generated in this study should be verified with
material from prospectively collected patient data or,
preferably, in a controlled clinical trial. Invariably, the
recurrence-free patients had lower risk scores than those
who developed distant metastases.
Comparison of molecular and immunohistochemical
classification
Primary tumours were classified separately into intrinsic
subtypes on the basis of molecular and IHC data. The com-
parison revealed that the agreement between molecular and
IHC classification was only ‘moderate’ (κ = 0.58; Table 1). In
a similar study, Chia and colleagues compared 347 tumours
[26]. Although they observed a slightly higher concordance
between molecular and histological classifications (κ = 0.64),
the two classifications were characterized by numerous mis-
classifications [26]. The results of both studies suggest that
molecular and immunohistochemical classifications are re-
lated but clearly not interchangeable.
Hierarchical clustering of primary tumours, local
recurrences and distant metastases
Primary tumours, local recurrences and brain metastases
were further characterized by hierarchical clustering
Fig. 4 Allocation of molecular scores among PAM50 intrinsic subtypes.
Molecular scores were measured from 87 primary cancers (including
control tumours and primary tumours from patients who developed
local recurrences or brain metastases). Scatter dot plots (median with
interquartile range) of RISK, ROR-P, RS, and EP are shown itemised into
intrinsic subtypes normal, lumA, lumB, Her2↑ and basal. The RS and EP
were only validated for ER+/Her2- tumours, therefore, ER- and/or
Her2+ tumours are shown exclusively for comparison (open circles)
Table 3 Allocation of molecular scores among PAM50 intrinsic
subtypes
lumA lumB Her2↑ basal
RISK normal < 0.01 0.17 0.01 0.02
lumA < 0.01 < 0.01 < 0.01
lumB < 0.01 < 0.01
Her2↑ 0.1
ROR-P normal 0.05 < 0.01 < 0.01 < 0.01
lumA < 0.01 < 0.01 < 0.01
lumB < 0.01 < 0.01
Her2↑ 0.07
RS normal 0.04 0.43 – –
lumA < 0.01 – –
lumB – –
Her2↑ –
EP Normal 0.32 0.25 – –
lumA < 0.01 – –
lumB – –
Her2↑ –
RISK, and ROR-P were calculated from all 87 primary tumours, RS and EP from
all 31 ER+/Her2- primary tumours as described. Scores were compared
between any two groups using the Mann-Whitney test. Shown are p-values of
all pairwise comparisons. Two-tailed p values > 0.05 were considered
not significant.
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(Fig. 1), revealing that most tumours with normal-like
and lumA subtypes were separated from Her2↑ and
basal subtypes, while lumB tumours were situated be-
tween the two clusters. A similar arrangement was de-
scribed in the two original studies that were based on 65
breast cancers of 42 individuals [4, 5] or 78 tumours and
cDNA microarrays with more than 8.000 genes [4, 5].
We also compared gene expression profiles of primary
tumours with profiles of corresponding recurrences from
the same patients. Local recurrences were also preferen-
tially of luminal subtype, like the corresponding primary
tumours, but the majority of matched samples were no-
ticeably unrelated and did not separate in the immediate
vicinity on the heatmap (Fig. 1). Our results probably do
not allow drawing further conclusions, but it seems re-
markable that many changes take place at the level of
gene expression between primary tumours and local re-
currences that arose later in the same area of the breast.
Other studies based on IHC concurrently reported that
more than 70% of primary tumours and local recur-
rences were lumA or lumB [27, 28].
In contrast, primary tumours that relapsed as brain
metastases were predominantly Her2↑ or basal (nine
and four of 19, respectively) and matched samples often
had the same intrinsic subtype. Moreover, 11 metastases
cluster next to their matched primary tumours on the
heatmap. Similar results were reported from a study
based on 20 pairs of primary tumours and brain metas-
tases. Seventeen metastases retained the same PAM50
subtype as their corresponding primary tumours and 12
primary tumours and metastases clustered close to each
other [29]. The comparison was based on 143 genes, 61
of which were the same as in our study. Other results
based on IHC showed that primary tumours with Her2-
enriched or basal subtype preferentially relapsed as brain
metastases [30, 31].
Comparison of molecular scores
Primary tumours that relapsed as brain metastases had
significantly higher scores than primary tumours that
remained recurrence-free (controls) (Fig. 2 and Table 2).
The results are shown for RISK and ROR-P. The RS and
EP were not included, as these scores were developed
and validated in ER+ tumours with normal Her2. In
addition, ER-, PR- and Her2- subscores from RISK were
also able to discriminate between tumors that relapsed
as brain metastases and recurrence-free controls. The
four molecular scores were also compared between
recurrence-free controls and primary tumours that re-
lapsed locally. We observed that molecular scores did
not increase when primary tumours relapsed as local re-
currence (Fig. 2, Table 2). This contradicts some earlier
reports that the molecular scores were higher in primary
tumours that relapsed as local recurrences when
compared to controls [32–34]. However, the different
definitions of local recurrence (e.g. recurrences in the
chest skin after mastectomy or any site in the breast
were considered local recurrence) may explain this ap-
parent discrepancy. It cannot be excluded that such tu-
mours have higher scores than local recurrences
according to our definition. In addition, none of these
earlier observations was validated in independent retro-
spective or prospective studies. Moreover, several groups
failed to find a molecular signature in primary tumours
discriminating between controls and tumours relapsing
as local recurrence. For instance, Servant and colleagues
tested 22 different gene-signatures, including RS and
found that none of them was able to predict ipsilateral
local recurrences [35]. In this study we tested RS and
other three additional scores and, similarly, found no dif-
ference between recurrence-free controls and primary
tumours that later reappeared as local relapse. There-
fore, patients at risk of local recurrence are probably
missed by the current molecular scores. In fact, a de
novo search for such markers might be successful as we
observed two genes, RBBP8 and MLL3, from our list of
84 genes whose expression was different in primary tu-
mours of local recurrences as compared to controls.
The RISK, RS, ROR-P and EP scores were originally
developed as prognostic parameters [6, 10, 12, 14]. Al-
though each score is computed from different genes,
their prognostic power seems to be similar and, it is pos-
sible that they can be used interchangeably. They are all
built from genes associated with proliferation; the RISK,
RS and EP scores contain additional genes related to ER
and the response to oestrogen. The ERBB2 gene which
codes for Her2, and the GRB7 gene are part of RISK and
RS. These two genes are physically linked on chromo-
some 17 and overexpression correlates with amplifica-
tion of DNA in this region of the chromosome.
The correlations between any two molecular scores
were 0.65 < ρ < 0.85 (Fig. 3a). While all the correlations
between PRO-subscores (genes related to proliferation)
were higher (0.82 ≤ ρ ≤ 0.97; panel B), the correlations
between ER-subscores (genes related to ER response)
were clearly lower (0.37 ≤ ρ ≤ 0.75; panel C). The impli-
cations of the lower correlations among ER-subscores
are not obvious and it should be clarified whether ER-
subscores could be improved by adding or replacing
some genes that are not consistently related to ER and
its response.
Our analyses are based on retrospectively collected
tumour samples. The results must thus be considered
cautiously, but they seem to indicate that the
proliferation-related genes (PRO-subscore) favour the
agreement between RISK, RS, ROR-P and EP, while the
ER-subscores are more variable and therefore limit the
agreement between the scores.
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Previous studies compared RS and EP [36], or RS and
ROR [37]. In these comparisons, RS was measured in
the laboratories of Genomic Heath. As a consequence,
the analyses and comparisons were based on separate
tissue sections, and RNAs were processed with different
assays and on different instruments. Nevertheless, the
studies reported similar results. We directly compared
RISK with RS that was either measured at Genomic
Health, or in our own laboratory, and we found higher
correlations when RS was measured on the same tissue
and in the same laboratory (ρ = 0.82, κ = 0.52 as com-
pared to ρ = 0.43, κ = 0.23). The comparison was based
on 220 prospectively collected samples (data not shown
and [38]).
The study presented here comprised 87 primary tu-
mours (43 recurrence-free controls, 25 primary tu-
mours of local recurrences and 19 primary tumours
of brain metastases). Each tumour was classified into
intrinsic subtypes according to PAM50. Twenty-nine
tumours were lumA; these tumours had the lowest
scores, corresponding to the best prognosis (Fig. 4).
Twenty-four tumours were lumB; the corresponding
scores were significantly higher than in lumA
(p < 0.01 for all scores). Sixteen primary tumours
were Her2↑ and 12 were basal, the corresponding
RISK and ROR-P scores were higher than lumB tu-
mours (p < 0.01) (Fig. 4, Table 3). This observation is
consistent with other studies [8] showing the lowest
scores for lumA tumours and higher scores in all
other subtypes.
Conclusions
In this study we measured four molecular scores – RISK,
RS, ROR-P and EP – in recurrence-free primary breast
cancer (controls) and in primary tumours that later re-
lapsed with a local recurrence or a brain metastasis. All
four scores performed similarly, and high pairwise corre-
lations were found between them. None of the four
scores allowed discriminating between recurrence-free
controls and primary tumours that relapsed with a local
recurrence. This observation is in conflict with other
studies that reported that RS and EP are prognostic for
both, local and distant recurrences. Our data confirmed
that primary tumours that later relapsed with a brain
metastasis had significantly higher RISK and ROR-P
scores. As many of these tumours were Her2↑, they did
not qualify for testing with RS and EP. We found that
primary tumours and corresponding brain metastases
were similar (at least with respect to gene expression).
This is in contrast to local recurrences where gene ex-
pression profiles of primary tumours and corresponding
local recurrences were surprisingly different. The results
may imply that tumour cells that survive from primary
tumours undergo major changes when they proliferate
and form local recurrences. This observation should be
considered when molecular scores derived from primary
tumours are used to estimate the risk of recurrence, or
even guide decisions on potential therapies.
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